Creative Planning
ZNTL icon

Creative Planning’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Creative Planning’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Hold
285,000
– – ﹤0.01% 2380
2026
Q1 		$667K Buy
285,000
+25,000
+10% +$64.6K ﹤0.01% 2793
2025
Q4 		$351K Hold
260,000
– – ﹤0.01% 3132
2025
Q3 		$393K Buy
260,000
+229,660
+757% +$344K ﹤0.01% 2938
2025
Q2 		$35.2K Sell
30,340
-206,183
-87% -$272K ﹤0.01% 3552
2025
Q1 		$376K Buy
236,523
+196,420
+490% +$424K ﹤0.01% 2559
2024
Q4 		$122K Buy
40,103
+28,803
+255% +$94.4K ﹤0.01% 3119
2024
Q3 		$41.6K Sell
11,300
-2,099
-16% -$7.63K ﹤0.01% 3110
2024
Q2 		$54.8K Buy
13,399
+1,809
+16% +$20.2K ﹤0.01% 2919
2024
Q1 		$183K Buy
11,590
+590
+5% +$8.12K ﹤0.01% 2596
2023
Q4 		$167K Buy
+11,000
New +$160K ﹤0.01% 2489

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Creative Planning's ZNTL Position: Q2 2026 in Review

Creative Planning held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 285,000 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Creative Planning first reported a position in ZNTL in Q4 2023 and has held it in 11 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Creative Planning held 285,000 shares of Zentalis Pharmaceuticals worth $1.38M as of Q2 2026.
  • Creative Planning left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2380 holding.
  • Creative Planning first reported a position in Zentalis Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.